SequelSEC

Praxis Precision Medicines, Inc. PRAX

Pharmaceutical Preparations · CIK 0001689548 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$326.20M
Fiscal year ended 2025-12-31
Free cash flow
-$249.12M
Fiscal year ended 2025-12-31

Praxis Precision Medicines, Inc. (PRAX) reported revenue of $0 and net income of -$303.27M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Praxis Precision Medicines, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Praxis Precision Medicines, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$0$8.55M$2.45M$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$326.20M-$200.16M-$126.37M-$214.99M
Net income-$303.27M-$182.82M-$123.28M-$214.03M
Research & development$267.12M$152.41M$86.77M$155.04M
Weighted-average diluted sharesshares 22.50Mshares 17.91Mshares 6.59Mshares 3.07M
Pretax income-$302.80M-$182.74M-$123.01MUnavailable
Income tax expense$471.00KUnavailableUnavailableUnavailable
Diluted EPS$-13.48$-10.21$-18.69$-69.65
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$59.08M$56.30M$42.05M$59.95M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Praxis Precision Medicines, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$357.33M$215.37M$81.30M$61.62M
Total assets$937.91M$483.11M$87.95M$115.13M
Current assets$610.91M$404.37M$84.88M$110.84M
Total liabilities$59.77M$37.66M$18.28M$39.02M
Current liabilities$59.77M$37.55M$15.75M$34.34M
Total equity incl. NCI$878.14M$445.45M$69.67M$76.11M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$24.63M$12.53M$5.82M$14.67M

Cash flow

Praxis Precision Medicines, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$249.07M-$131.76M-$111.14M-$185.04M
Capital expenditures$56.00K$0$50.00K$444.00K
Investing cash flow-$311.15M-$248.49M$38.95M$96.89M
Financing cash flow$702.17M$514.32M$91.87M$10.46M
Net change in cash$141.96M$134.07M$19.68M-$77.69M
Stock-based compensation$33.94M$41.36M$24.86M$28.59M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Praxis Precision Medicines, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$249.12M-$131.76M-$111.19M-$185.49M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-2340.3%-5164.4%Unavailable
FCF marginUnavailable-1540.5%-4543.8%Unavailable
SBC / revenueUnavailable483.6%1015.8%Unavailable
Current ratio10.22x10.77x5.39x3.23x
Revenue YoY growth-100.0%249.5%UnavailableUnavailable
Net marginUnavailable-2137.5%-5037.9%Unavailable
R&D / revenueUnavailable1782.0%3545.8%Unavailable
CapEx / revenueUnavailable0.0%2.0%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PRAX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-02View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.